Analysts’ Viewpoint on Transplant Drug Monitoring Assay Market Scenario
Therapeutic drug monitoring (TDM) of transplant medicine plays a crucial role in helping health care professionals maintain plasma and blood levels of immunosuppressants within their respective therapeutic ranges. TDM ensures that concentrations are not too low or too high, thereby minimizing the risks of rejection or toxicity, respectively. Leading players operating in the healthcare industry offer a full line of Immunosuppressant Drug Monitoring (ISD) assays, such as mycophenolic acid, cyclosporine, everolimus, and tacrolimus, to aid in patient monitoring. Rise in healthcare expenditure, improvement in healthcare infrastructure, increase in global per capita income, and government reimbursement programs are likely to create lucrative opportunities for companies operating in the transplant drug monitoring assay market in the next few years.
The global transplant drug monitoring assay market is expected to grow at a rapid pace during the forecast period from 2022 to 2031, owing to the increase in need for organ transplantation, surge in R&D funding, and rise in prevalence of chronic liver and kidney diseases. Increase in need for point-of-care therapeutic drug monitoring and home-based therapeutic drug monitoring is likely to create lucrative opportunities for players operating in the global transplant drug monitoring assay market during the forecast period.
Rise in incidence of chronic diseases of the liver, heart, kidney, and pancreas along with blood disorders such as leukemia and aplastic anemia are driving the demand for organ transplants/replacements. This is expected to boost the global transplant drug monitoring assay market. According to the Health Resources & Services Administration (HRSA), around 40,000+ transplants were performed across the globe in 2021. According to the World Health Organization (WHO), the global geriatric population stood at around 524 million in 2010 and is anticipated to reach 1.5 billion by 2050. The world is aging at a rapid pace, especially in developed countries such as the U.S., Germany, and Japan. For instance, the U.S. Census Bureau stated in 2010 that people older than 65 years represented around 12.4% of the total population in 2000, and the percentage is expected to reach 19% in the U.S. by 2030. Surge in geriatric population directly affects the growth and demand for organ transplants, primarily due to their higher susceptibility to kidney and heart diseases.
The number of organ donors across the globe has been rising due to the initiatives by government organizations. Various government authorities across developed and developing countries support organ donation through awareness programs, financial assistance, and effective schemes and policies. In April 2022, the Government of Canada announced the investment of US$ 2 Mn for research in innovative organ and tissue donation.
In November 2019, the Spanish Ministry of Health, Consumer Affairs and Social Welfare and the World Health Organization (WHO) signed an agreement for fostering cooperation in the field of donation and transplantation of organs, cells, and tissues. This technical agreement will lead to the creation of the Global Observatory on Donation and Transplantation 'GODT', which will collect and manage global data on clinical and regulatory information regarding organ transplants. Thus, government support for organ donation is expected to create significant opportunities in the global transplant drug monitoring assay market.
In terms of product, the global transplant drug monitoring assay market has been bifurcated into equipment and consumables. The equipment segment held major share of the global market in 2021. The segment is projected to grow at a rapid pace during the forecast period. Clinical chemistry analyzers and immunoassay analyzers provide mid-to high-volume laboratories the flexibility to improve efficiencies and economics. With a throughput of excellent onboard parameters, this equipment delivers field-proven reliability and efficiency to laboratories worldwide. Additionally, leading players such as Thermo Scientific are coming up with innovative solutions such as ‘QMS Everolimus’. This analyzer carries the CE mark for usage in the European Union for liver transplant drug monitoring.
Based on technology, the global transplant drug monitoring assay market has been classified into chromatography-MS and immunoassays. Chromatography-MS is a rapidly growing segment of the global transplant drug monitoring assay market. The segment is expected to advance at a CAGR of 12.2% during the forecast period. Growth of the segment can be ascribed to the rise in demand for organ transplantation across the globe. Currently, 121,678 people are waiting for lifesaving organ transplants in the U.S.
Based on drug, the global transplant drug monitoring assay market has been split into tacrolimus, cyclosporin, methotrexate, and others. The tacrolimus segment held major share of the global market in 2021. Recent FDA approval for tacrolimus as a transplantation drug is projected to drive the segment during the forecast period. In July 2021, the U.S. Food and Drug Administration (FDA) approved the usage of the transplant drug tacrolimus for the prevention of organ rejection in pediatric and adult patients receiving lung transplants. Furthermore, nearly 85% of kidney transplant recipients have been prescribed tacrolimus as a maintenance immunosuppressive regimen, primarily due to its higher potency, and lower rejection and nephrotoxicity compared to cyclosporine.
Based on end-user, the global transplant drug monitoring assay market has been divided into hospital laboratories, commercial & private laboratories, and others. The hospital laboratories segment held prominent share of the global market in 2021. The segment is likely to expand at the fastest CAGR during the forecast period. TDM assays are increasingly provided in hospitals and ambulatory surgical centers with multiple medical specialties. These services are managed entirely by hospital pharmacists. Hence, these pharmacists assume a crucial role in ensuring the optimal use of TDM assays. Additionally, rise in number of government and private hospital laboratories in emerging economies, such as China and India, and increase in incidence of cardiovascular and chronic liver diseases are driving the segment. Surge in patient base is encouraging hospital laboratories to form alliances and strategic partnerships. This is also likely to propel the segment.
North America accounted for major share of around 35% of the global transplant drug monitoring assay market in 2021. North America’s dominance can be ascribed to improvements in technology, surgical techniques, and immunosuppressive drugs along with rise in success rate of organ transfer procedures. Additionally, rapid adoption of advanced treatments, increase in R&D activities, high affordability, and rise in prevalence of chronic diseases, including chronic kidney diseases and CVDs, are driving the demand for organ transplantation. This is likely to boost the transplant drug monitoring assay market in North America.
Europe and Asia Pacific are also large markets for transplant drug monitoring assays. These regions held the second and third largest share, respectively, of the global market in 2021. The transplant drug monitoring assay market in Asia Pacific is driven by the rise in focus on organ donation. Strong presence of Siemens Healthineers AG, Hologic, Inc., Danaher Corporation, and Bio-Rad Laboratories, Inc., specifically in China, India, and South Korea, is also expected to augment the market in Asia Pacific. The market in Latin America is projected to grow at a faster pace than that in Middle East & Africa.
The global transplant drug monitoring assay market is consolidated, with the presence of a small number of leading players. Most of the companies are investing significantly in research & development activities, primarily to introduce innovative assays. Furthermore, diversification of product portfolios and mergers & acquisitions are the key strategies adopted by the leading players. Abbott, Thermo Fisher Scientific Inc., H.U. Group Holdings, Inc. (Fujirebio Holdings, Inc.), Hoffmann-La Roche Ltd., Siemens Healthineers AG, Hologic, Inc., Danaher Corporation, and Bio-Rad Laboratories, Inc. are the key players in the transplant drug monitoring assay market.
Each of these players has been profiled in the transplant drug monitoring assay market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 198.0 Mn |
|
Market Forecast Value in 2031 |
More than US$ 542 Mn |
|
Growth Rate (CAGR) |
11.0% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global transplant drug monitoring assay market was valued at US$ 198.0 Mn in 2021.
The global transplant drug monitoring assay market is projected to reach more than US$ 542 Mn by 2031.
The global transplant drug monitoring assay market grew at a CAGR of 1% from 2017 to 2021.
The global transplant drug monitoring assay market is anticipated to grow at a CAGR of 11.0% from 2022 to 2031.
Increase in incidence of chronic diseases leading to organ failure and technologically advanced products propel the global transplant drug monitoring assay market.
The tacrolimus segment held over 60% share of the global transplant drug monitoring assay market in 2021.
Prominent players in the global transplant drug monitoring assay market include Hologic, Inc., Abbott, Thermo Fisher Scientific Inc., H.U. Group Holdings, Inc. (Fujirebio Holdings, Inc.), and Siemens Healthineers AG.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Transplant Drug Monitoring Assay Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pricing Analysis of Drugs (Tacrolimus, Methotrexate and Cyclosporin)
5.2. Volume Units of Transplant Drugs in 2018-2021 (Tacrolimus, Methotrexate and Cyclosporin)
5.3. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long-term impact)
6. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Consumables
6.3.2. Equipment
6.3.2.1. Immunoassay Analyzers
6.3.2.2. Chromatography & MS Detectors
6.3.2.3. Clinical Chemistry Analyzers
6.4. Market Attractiveness Analysis, By Product
7. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Drug
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug, 2017–2031
7.3.1. Tacrolimus
7.3.2. Methotrexate
7.3.3. Cyclosporin
7.3.4. Others
7.4. Market Attractiveness Analysis, By Drug
8. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Technology
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Technology , 2017–2031
8.3.1. Immunoassays
8.3.2. Chromatography-MS
8.3.3. Others
8.4. Market Attractiveness Analysis, By Technology
9. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospital Laboratories
9.3.2. Commercial & Private Laboratories
9.3.3. Others
9.4. Market Attractiveness Analysis, By End-user
10. Global Transplant Drug Monitoring Assay Market Analysis and Forecast, By Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, By Region
11. North America Transplant Drug Monitoring Assay Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Consumables
11.2.2. Equipment
11.2.2.1. Immunoassay Analyzers
11.2.2.2. Chromatography & MS Detectors
11.2.2.3. Clinical Chemistry Analyzers
11.3. Market Value Forecast, by Drug, 2017–2031
11.3.1. Tacrolimus
11.3.2. Methotrexate
11.3.3. Cyclosporin
11.3.4. Others
11.4. Market Value Forecast, by Technology, 2017–2031
11.4.1. Immunoassays
11.4.2. Chromatography-MS
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospital Laboratories
11.5.2. Commercial & Private Laboratories
11.5.3. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Drug
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Transplant Drug Monitoring Assay Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Consumables
12.2.2. Equipment
12.2.2.1. Immunoassay Analyzers
12.2.2.2. Chromatography & MS Detectors
12.2.2.3. Clinical Chemistry Analyzers
12.3. Market Value Forecast, by Drug, 2017–2031
12.3.1. Tacrolimus
12.3.2. Methotrexate
12.3.3. Cyclosporin
12.3.4. Others
12.4. Market Value Forecast, by Technology, 2017–2031
12.4.1. Immunoassays
12.4.2. Chromatography-MS
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospital Laboratories
12.5.2. Commercial & Private Laboratories
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Drug
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Transplant Drug Monitoring Assay Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Consumables
13.2.2. Equipment
13.2.2.1. Immunoassay Analyzers
13.2.2.2. Chromatography & MS Detectors
13.2.2.3. Clinical Chemistry Analyzers
13.3. Market Value Forecast, by Drug, 2017–2031
13.3.1. Tacrolimus
13.3.2. Methotrexate
13.3.3. Cyclosporin
13.3.4. Others
13.4. Market Value Forecast, by Technology, 2017–2031
13.4.1. Immunoassays
13.4.2. Chromatography-MS
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospital Laboratories
13.5.2. Commercial & Private Laboratories
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Drug
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Transplant Drug Monitoring Assay Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Consumables
14.2.2. Equipment
14.2.2.1. Immunoassay Analyzers
14.2.2.2. Chromatography & MS Detectors
14.2.2.3. Clinical Chemistry Analyzers
14.3. Market Value Forecast, by Drug, 2017–2031
14.3.1. Tacrolimus
14.3.2. Methotrexate
14.3.3. Cyclosporin
14.3.4. Others
14.4. Market Value Forecast, by Technology , 2017–2031
14.4.1. Immunoassays
14.4.2. Chromatography-MS
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospital Laboratories
14.5.2. Commercial & Private Laboratories
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Drug
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Transplant Drug Monitoring Assay Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Consumables
15.2.2. Equipment
15.2.2.1. Immunoassay Analyzers
15.2.2.2. Chromatography & MS Detectors
15.2.2.3. Clinical Chemistry Analyzers
15.3. Market Value Forecast, by Drug, 2017–2031
15.3.1. Tacrolimus
15.3.2. Methotrexate
15.3.3. Cyclosporin
15.3.4. Others
15.4. Market Value Forecast, by Technology , 2017–2031
15.4.1. Immunoassays
15.4.2. Chromatography-MS
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospital Laboratories
15.5.2. Commercial & Private Laboratories
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Drug
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company, 2021
16.3. Company Profiles
16.3.1. Abbott
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Company Financials
16.3.1.3. Growth Strategies
16.3.1.4. SWOT Analysis
16.3.2. Thermo Fisher Scientific, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Company Financials
16.3.2.3. Growth Strategies
16.3.2.4. SWOT Analysis
16.3.3. H.U. Group Holdings Inc. (Fujirebio Holdings, Inc.)
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Company Financials
16.3.3.3. Growth Strategies
16.3.3.4. SWOT Analysis
16.3.4. Hoffmann-La Roche Ltd.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Company Financials
16.3.4.3. Growth Strategies
16.3.4.4. SWOT Analysis
16.3.5. Siemens Healthineers AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Company Financials
16.3.5.3. Growth Strategies
16.3.5.4. SWOT Analysis
16.3.6. Hologic, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Company Financials
16.3.6.3. Growth Strategies
16.3.6.4. SWOT Analysis
16.3.7. Danaher Corporation
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Company Financials
16.3.7.3. Growth Strategies
16.3.7.4. SWOT Analysis
16.3.8. Bio-Rad Laboratories, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Company Financials
16.3.8.3. Growth Strategies
16.3.8.4. SWOT Analysis
List of Tables
Table 01: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031
Table 03: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 04: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031
Table 05: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 09: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031
Table 10: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 11: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031
Table 12: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031
Table 16: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 17: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031
Table 18: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 21: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031
Table 22: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 23: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031
Table 24: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 27: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031
Table 28: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 29: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031
Table 30: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 33: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Equipment, 2017–2031
Table 34: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Technology, 2017–2031
Table 35: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by Drug, 2017–2031
Table 36: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031
Figure 02: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031
Figure 03: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Consumables, 2017–2031
Figure 04: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Equipment, 2017–2031
Figure 05: Global Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031
Figure 06: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031
Figure 07: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Immunoassays, 2017–2031
Figure 08: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Chromatography-MS, 2017–2031
Figure 09: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Others, 2017–2031
Figure 10: Global Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031
Figure 11: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031
Figure 12: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Tacrolimus, 2017–2031
Figure 13: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Methotrexate, 2017–2031
Figure 14: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Cyclosporin, 2017–2031
Figure 15: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Others, 2017–2031
Figure 16: Global Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031
Figure 17: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031
Figure 18: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Hospital Laboratories, 2017–2031
Figure 19: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Commercial & Private Laboratories, 2017–2031
Figure 20: Global Transplant Drug Monitoring (TDM) Assay Market (US$ Mn), by Others, 2017–2031
Figure 21: Global Transplant Drug Monitoring (TDM) Assay Market, by Region, 2021 and 2031
Figure 22: Global Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Region, 2022–2031
Figure 23: North America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031
Figure 24: North America Transplant Drug Monitoring (TDM) Assay Market, by Country, 2021 and 2031
Figure 25: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country, 2022–2031
Figure 26: North America Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031
Figure 27: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031
Figure 28: North America Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031
Figure 29: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031
Figure 30: North America Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031
Figure 31: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031
Figure 32: North America Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031
Figure 33: North America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031
Figure 34: Europe Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031
Figure 35: Europe Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region, 2021 and 2031
Figure 36: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 37: Europe Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031
Figure 38: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031
Figure 39: Europe Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031
Figure 40: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031
Figure 41: Europe Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031
Figure 42: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031
Figure 43: Europe Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031
Figure 44: Europe Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031
Figure 45: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region/Sub-region, 2021 and 2031
Figure 47: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 48: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031
Figure 49: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031
Figure 50: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031
Figure 51: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031
Figure 52: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031
Figure 53: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031
Figure 54: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031
Figure 55: Asia Pacific Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031
Figure 56: Latin America Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031
Figure 57: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region, 2021 and 2031
Figure 58: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 59: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031
Figure 60: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031
Figure 61: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031
Figure 62: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031
Figure 63: Latin America Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031
Figure 64: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031
Figure 65: Latin America Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031
Figure 66: Latin America Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031
Figure 67: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Value (US$ Mn) Forecast, 2017–2031
Figure 68: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Country/Sub-region, 2021 and 2031
Figure 69: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 70: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Product, 2021 and 2031
Figure 71: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Product, 2022–2031
Figure 72: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Technology, 2021 and 2031
Figure 73: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Technology, 2022–2031
Figure 74: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by Drug, 2021 and 2031
Figure 75: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by Drug, 2022–2031
Figure 76: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market, by End-user, 2021 and 2031
Figure 77: Middle East & Africa Transplant Drug Monitoring (TDM) Assay Market Attractiveness Analysis, by End-user, 2022–2031
Figure 78: Global Transplant Drug Monitoring (TDM) Assay Market Share Analysis/Ranking, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Transplant Drug Monitoring Assay Market
